TScan Therapeutics Inc (TCRX)

[FACT-MASTER]

No, but there could be merit in using the (TCR) approach in a select population of patients who unable to undergo an HSCT.

In AML that would be patients at a high risk of relapse, as defined by CR following induction, but are MRD+, and/or with incomplete recovery of neutrophil (CRi) or platelet counts (CRp). In that group more than 80% will relapse within the first year no matter what is (currently) done after induction therapy https://ascopubs.org/doi/full/10.1200/JCO.2014.58.3518

The wisdom of your response above, is duly understood.

The prognosis for the condition you have outlined above is very poor, ( lost a friend and business colleague to pretty much exactly this condition in 2022).


One factor that i've thought about though, is the possibility of a "mutational footprint " left by some induction therapies and if that would effect the TScan tech. From the recent display of data, it doesn't appear to be an issue.

The other articles you posted are highly informative, imo - still reading